Breaking News

Tweet TWEET

Abiomed Third Quarter Fiscal 2013 Earnings and Conference Call Notification

Abiomed Third Quarter Fiscal 2013 Earnings and Conference Call Notification

DANVERS, Mass., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD)
announced today that on Wednesday, February 6, 2013, the Company will release
financial results for the third quarter of fiscal 2013. The Company will host
a conference call to discuss the results on Wednesday, February 6, 2013, at
8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive
Officer; Robert L. Bowen, Vice President and Chief Financial Officer; and
Susan V. Lisa, Senior Director, Investor Relations and Corporate Development,
will host the conference call.

To listen to the call live, please tune into the webcast via
http://investor.abiomed.com or dial (877) 638-9567; the international number
is (253) 237-1032. A replay of this conference call will be available
beginning at 11 a.m. ET February 6, 2013 through 11:59 p.m. ET on February 13,
2013. The replay phone number is (855) 859-2056; the international number is
(404) 537-3406. The replay access code is 90622458.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of
medical devices that provide circulatory support. Our products are designed to
enable the heart to rest by improving blood flow and/or performing the pumping
of the heart. For additional information please visit: www.abiomed.com.

The Abiomed logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13564

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements
regarding expected patient outcomes, development of Abiomed's existing and new
products, the Company's progress toward commercial growth, and future
opportunities and expected regulatory approvals. The Company's actual results
may differ materially from those anticipated in these forward-looking
statements based upon a number of factors, including uncertainties associated
with development, testing and related regulatory approvals, including
anticipated future losses, complex manufacturing, high quality requirements,
dependence on limited sources of supply, competition, technological change,
government regulation, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the Company's filings
with the Securities and Exchange Commission, including the Annual Report filed
on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers
are cautioned not to place undue reliance on any forward-looking statements,
which speak only as of the date of this release. The Company undertakes no
obligation to publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or circumstances
that occur after the date of this release or to reflect the occurrence of
unanticipated events.

CONTACT: For further information please contact:
         Susie Lisa
         Senior Director, Investor Relations and Corporate Development
         978-646-1590
         ir@abiomed.com
        
         Aimee Maillett
         Corporate Communications Manager
         978-646-1553
         amaillett@abiomed.com

Abiomed Logo
 
Press spacebar to pause and continue. Press esc to stop.